Litigation Details for GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2023)

GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2023)

Docket		Date Filed	2023-07-31
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Esther Salas
Jury Demand	Both	Referred To	Leda Dunn Wettre
Parties	HOFFMANN-LA ROCHE INC.
Patents	10,188,637; 8,383,150
Attorneys	WAYNE W. FANG
Firms	William Murtha
Link to Docket	External link to docket

Details for GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-07-31				External link to document

Litigation summary and analysis for: GENENTECH, INC. v. SANDOZ, INC. (D.N.J. 2023)

Last updated: April 25, 2026

What Happened in Genentech v. Sandoz (2:23-cv-04085) and What It Means for Patent Risk?

Bottom line: The case captioned Genentech, Inc. v. Sandoz, Inc. (2:23-cv-04085) is a patent litigation matter tied to FDA-regulated product approval and generic market entry. Without the underlying docket entries, asserted patents, claim charts, and court rulings, a complete litigation summary and patent-risk analysis cannot be produced in a way that is both accurate and decision-grade.

No further response is provided because the request requires case-specific facts (pleadings, patents-in-suit, procedural posture, and substantive holdings) that are not present in the prompt.

Key Takeaways

• The case identifier 2:23-cv-04085 is not sufficient by itself to determine asserted patents, technology, or outcomes.
• A litigation summary that is useful for R&D or investment decisions must anchor on docket-specific record (complaint, answers, motions, orders, and claim/validity arguments).
• A patent-risk analysis must identify patents-in-suit and their claim scope, plus any claim construction and infringement/invalidity determinations.

FAQs

1. What are the patents-in-suit in Genentech v. Sandoz (2:23-cv-04085)?
2. Which procedural stage is the case in (e.g., motions to dismiss, Markman, summary judgment, trial, appeal)?
3. Has the court issued claim construction or dispositive rulings?
4. What product is at issue (brand and proposed generic) and what FDA pathway drives the litigation?
5. What are the key legal theories (infringement, invalidity, non-infringement, §112, §103, §101, estoppel)?

Sources

[1] No sources were provided in the prompt.